NAFDAC Destroys Counterfeit Products Worth Over N75 Million in Abuja

Image Credit: © Trueffelpix |

November 18, 2016 – The National Agency for Food and Drug Administration and Control (NAFDAC), recently carried out a destruction exercise in Abuja where the agency disposed of expired medication, counterfeit drugs, and other regulated products estimated to be worth over N75 million.

The Acting Director General of the agency, Mrs. Yetunde Oni who spoke at a press briefing before the destruction exercise, stated that NAFDAC is winning the war against counterfeiting in Nigeria and emphasized that some of products were voluntarily delivered to NAFDAC by other organizations.

“Today, we witness the destruction of various categories of regulated products as one of the strategies employed by NAFDAC to prevent the circulation of fake, counterfeit medicines and unwholesome regulated products. These products are worth over N75 million. We must stress that some of these products were voluntarily submitted to NAFDAC by various governmental and non-governmental organizations whilst others were mopped up from open market via enforcement activities and surveillance system of NAFDAC,” she said.

On the current status of NAFDAC laws as it relates to counterfeiting and quality control, the Director General stated that the agency is in the process of reviewing its laws to enable it perform optimally.

“Permit me to state here that our laws are being reviewed to make the business of counterfeiting no longer business as usual and very unattractive to those people who engage in wanting to kill innocent citizens all because of business. We are optimistic that in the near future we would have nothing to destroy as we work toward ensuring availability of good, quality, safe and affordable medicines and wholesome regulated products to the Nigerian populace.”

Print Friendly, PDF & Email
About Bob Aroture 564 Articles
Bob is a Senior Editor and Content Development Manager at Nigerian Law Intellectual Property Watch. He holds a BS degree, with a major in biochemistry. He works directly with the Newsroom Team. His focus areas are technology and innovation, and pharmaceutical technology. Email: